NeoTX Overview
NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies. STR binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The technology effectively converts a weak immune response against the tumor to a powerful yet safe native antibacterial immune reaction. The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors.
Cumulative Funding Raised Over Time ($)
$2.5MDec 2015
$11.3MDec 2017
$56.3MFeb 2020
$65.5MOct 2016
Latest News
growth-positive
Curing cancer is no small feat: Israel's NeoTX is still up for the challenge
Israeli startup NeoTX, a biopharmaceutical company focused on oncology research and development, is using its Tumor Targeted Superantigen (TTS) platform technology to coat tumors with a superantigen and activate the bodys immune system to attack cancer cells. The TTS technology has the potential to challenge the effectiveness of other cancer treatments. NeoTXs CEO, Asher Nathan, discussed the companys unique approach to oncology and its goal of becoming a leading company for oncology treatment. The company, founded in 2015, has raised over $80 million and is headquartered in Rehovot, Israel.
Expand
growth-positive
NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)
NeoTX Therapeutics has successfully completed the first stage of a clinical trial for its drug naptumomab estafenatox in combination with docetaxel for advanced non-small cell lung cancer patients. The trial showed promising results, providing new treatment options for patients. Additionally, NeoTX recently completed the acquisition of InterX, a computer-aided drug discovery company, which strengthens its drug discovery capabilities. NeoTX plans to investigate the combination of naptumomab estafenatox with checkpoint inhibitors in various indications. NeoTX is a vertically integrated clinical-stage immuno-oncology drug development company utilizing its proprietary Tumor Targeted Superantigen platform.
PartnersAcquisition
growth-positive
NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM
NeoTX has announced the acquisition of InterX, a drug discovery company utilizing advanced proprietary tools for the discovery and design of therapeutic molecules. This acquisition expands NeoTXs capabilities and comes with a pipeline of early drugs. The technologies acquired have the potential to increase the speed of drug discovery and save time in the typical drug discovery timeline. NeoTX aims to advance best-in-class drug candidates and increase the value of its pipeline. The Chief Scientist of NeoTX and co-founder of InterX, Nobel Prize Laureate Prof. Roger Kornberg, has assumed the role of Chairman of the Board of NeoTX.
Acquisition
growth-positive
NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer
NeoTX Therapeutics has announced the promotion of Marcel Rozencweig to President and the appointment of Scott Z. Fields as the new chief medical officer. Rozencweig, the current CMO, will help accelerate growth and expand strategic industry partnerships, while Fields brings over 30 years of experience in clinical drug development. The company is delighted with the new additions to its leadership team and believes their expertise will be valuable for clinical development and registration strategies. NeoTX is a clinical-stage immuno-oncology company developing targeted anticancer immunotherapies.
Management Changes
growth-positive
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
NeoTX Therapeutics will participate in the LifeSci Partners Private Company Virtual Summer Symposium to deliver a corporate update to potential investors and strategic partners. The presentation will cover recent and upcoming milestones, as well as the clinical progress of their lead candidate in a Phase 1b clinical trial for the treatment of advanced and metastatic solid tumors. The lead candidate is being evaluated in combination with AstraZenecas checkpoint inhibitor. The symposium will feature presentations from over 130 private healthcare companies and panel discussions with industry leaders and investment communities.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $65.5M |
| Last funding | $45M |
| Stage | C |
| Rounds | 4 |
| Investors | 5 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | neotx.com/ |
| Careers | Careers page |
Locations
Prof. Haim Pekeris Street 2, Rehovot, Israel
Photos & Videos
3 item(s)
NeoTX Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (10)
drug-developmentdrug-discoverybiopharmaceuticalcancer-therapyoncologycancertherapeuticsimmunotherapycell-therapypharmaceuticalsNeoTX Financials
$65.5M
Total funding
Undisclosed
Capital raised
$45M
Last funding
C
Funding stage
4
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
$2.5MDec 2015
$11.3MDec 2017
$56.3MFeb 2020
$65.5MOct 2016
Private Equity Funding
C Round
Feb 2020
$45M
J. Tomilson Hil, Maurice Greenberg, NFDOS, Tako Ventures
B Round
Dec 2017
$8.8M
Starr Ventures
A Round
Oct 2016
$9.2M
Starr Ventures
Seed
Dec 2015
$2.5M
Mergers & Acquisitions
MNAEvent
May 2022
Undisclosed
NeoTX Lifecycle
Cumulative Funding Raised Over Time
$2.5MDec 2015
$11.3MDec 2017
$56.3MFeb 2020
$65.5MOct 2016
All Events
C Round
Feb 2020
$45M
J. Tomilson Hil, Maurice Greenberg, NFDOS, Tako Ventures
B Round
Dec 2017
$8.8M
Starr Ventures
A Round
Oct 2016
$9.2M
Starr Ventures
Seed
Dec 2015
$2.5M
MNAEvent
May 2022
Undisclosed
NeoTX News
10 articles
growth-positive
Curing cancer is no small feat: Israel's NeoTX is still up for the challenge
Israeli startup NeoTX, a biopharmaceutical company focused on oncology research and development, is using its Tumor Targeted Superantigen (TTS) platform technology to coat tumors with a superantigen and activate the bodys immune system to attack cancer cells. The TTS technology has the potential to challenge the effectiveness of other cancer treatments. NeoTXs CEO, Asher Nathan, discussed the companys unique approach to oncology and its goal of becoming a leading company for oncology treatment. The company, founded in 2015, has raised over $80 million and is headquartered in Rehovot, Israel.
Expand
growth-positive
NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)
NeoTX Therapeutics has successfully completed the first stage of a clinical trial for its drug naptumomab estafenatox in combination with docetaxel for advanced non-small cell lung cancer patients. The trial showed promising results, providing new treatment options for patients. Additionally, NeoTX recently completed the acquisition of InterX, a computer-aided drug discovery company, which strengthens its drug discovery capabilities. NeoTX plans to investigate the combination of naptumomab estafenatox with checkpoint inhibitors in various indications. NeoTX is a vertically integrated clinical-stage immuno-oncology drug development company utilizing its proprietary Tumor Targeted Superantigen platform.
PartnersAcquisition
growth-positive
NEOTX ACQUIRES INTERX, ADDS WORLD CLASS DISCOVERY ARM
NeoTX has announced the acquisition of InterX, a drug discovery company utilizing advanced proprietary tools for the discovery and design of therapeutic molecules. This acquisition expands NeoTXs capabilities and comes with a pipeline of early drugs. The technologies acquired have the potential to increase the speed of drug discovery and save time in the typical drug discovery timeline. NeoTX aims to advance best-in-class drug candidates and increase the value of its pipeline. The Chief Scientist of NeoTX and co-founder of InterX, Nobel Prize Laureate Prof. Roger Kornberg, has assumed the role of Chairman of the Board of NeoTX.
Acquisition
growth-positive
NeoTX Therapeutics promotes Marcel Rozencweig, M.D., to President and welcomes Scott Z. Fields, M.D., as new Chief Medical Officer
NeoTX Therapeutics has announced the promotion of Marcel Rozencweig to President and the appointment of Scott Z. Fields as the new chief medical officer. Rozencweig, the current CMO, will help accelerate growth and expand strategic industry partnerships, while Fields brings over 30 years of experience in clinical drug development. The company is delighted with the new additions to its leadership team and believes their expertise will be valuable for clinical development and registration strategies. NeoTX is a clinical-stage immuno-oncology company developing targeted anticancer immunotherapies.
Management Changes
growth-positive
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
NeoTX Therapeutics will participate in the LifeSci Partners Private Company Virtual Summer Symposium to deliver a corporate update to potential investors and strategic partners. The presentation will cover recent and upcoming milestones, as well as the clinical progress of their lead candidate in a Phase 1b clinical trial for the treatment of advanced and metastatic solid tumors. The lead candidate is being evaluated in combination with AstraZenecas checkpoint inhibitor. The symposium will feature presentations from over 130 private healthcare companies and panel discussions with industry leaders and investment communities.
Partners
growth-positive
Cancer Immunotherapy Startup NeoTX Raises $45 Million
Israeli cancer immunotherapy company NeoTX has raised $45 million in a series C funding round. The funds will be used to advance its selective T-cell redirection molecule for the treatment of advanced and metastatic solid tumors. NeoTX uses Selective T cell Redirection (STR) technology to encourage a more effective immune response against cancer tumors. The companys lead STR molecule is naptumomab estafenatox (Nap), a fusion protein that binds to an antigen expressed by different tumor cells. NeoTX has raised a total of $60 million to date.
Investment
growth-positive
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
NeoTX Therapeutics has announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (Nap) in combination with AstraZenecas checkpoint inhibitor IMFINZI® (durvalumab) for the treatment of advanced or metastatic solid tumors. The company aims to establish the maximum tolerated dose in the dose-escalation Phase 1b study before advancing to a cohort expansion study. This milestone marks the initiation of studies in the NeoTX-AstraZeneca collaboration. The article discusses the STR platform, the potential of Nap in combination with checkpoint inhibitors, and the target patient population.
Partners
growth-positive
Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
Active Biotech announces that their partner NeoTX enters a clinical collaboration with AstraZenecas MedImmune to support Phase 1b/2 studies investigating ANYARA in combination with AstraZenecas IMFINZI. NeoTX will sponsor the study, while AstraZeneca will supply durvalumab. The collaboration validates the project and is an important step towards the start of the clinical study.
Partners
growth-positive
Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer
Active Biotech announces that its partner NeoTX Therapeutics will present new data for ANYARA at the Annual Meeting of the American Association for Cancer Research. The data demonstrates a synergistic anti-tumor effect when ANYARA is combined with a PD-1 checkpoint inhibitor in several different tumor models. Active Biotech is enthusiastic about the potential clinical benefit of this combination therapy.
Partners
growth-positive
Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology
Active Biotech has entered into a licensing agreement with NeoTX Therapeutics for its investigational compound Naptomumab estafenatox (ANYARA) for cancer immunotherapy. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug. This partnership is a key milestone in NeoTXs strategy to bring tumor recognition enhancing therapeutics to the market. The agreement grants NeoTX exclusive rights to develop and commercialize ANYARA worldwide in cancer indications. The total deal value amounts to $71 million, with an initial payment of $250,000 upon signing. Active Biotech will receive progressive, double-digit royalties on NeoTXs net sales. ANYARA is a Tumor Targeting Superantigen compound that increases the ability of the immune system to recognize the tumor. Positive data has been reported from clinical Phase I trials in lung cancer, renal cell cancer, and pancreatic cancer.
Partners
NeoTX Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 15 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
NeoTX Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515220929 |
| Crunchbase | predictive-therapeutics |
| Phone | +97239125853 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-01-18T00:00:00.000Z |
| Created | 2019-08-12T00:00:00.000Z |